US2015240288A1PendingUtilityA1

Lyophilised dabigatran

Assignee: BOEHRINGER INGELHEIM INTPriority: Feb 2, 2009Filed: May 12, 2015Published: Aug 27, 2015
Est. expiryFeb 2, 2029(~2.5 yrs left)· nominal 20-yr term from priority
A61P 7/02A61K 31/4439G01N 2496/45C12Q 1/56A61K 9/19G01N 2496/00G01N 2333/974G01N 33/96G01N 33/94G01N 2430/00
24
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a lyophilised form of dabigatran of formula I its use as a calibrator in the assays for the determination of pharmacodinamic effects of dabigatran etexilate as well as such assays per se.

Claims

exact text as granted — not AI-modified
1 - 4 . (canceled) 
     
     
         5 . The lyophilized dabigatran made by the process comprising the steps of:
 (1) dissolving dabigatran in 1M HCl and diluting with purified water to make a dabigatran stock solution,   (2) diluting aliquots of dabigatran stock solution with human anticoagulated plasma to provide final solutions having different nanomolar concentrations of dabigatran, wherein the human anticoagulated plasma is human citrated plasma or EDTA-anticoagulated plasma, and   (3) freeze-drying aliquots of the thus obtained final solutions to be used as lyophilized calibrator agents or lyophilized calibrator agents in an anticoagulant assay, optionally storing lyophilized calibrators at −20 ° C.   
     
     
         6 . The lyophilized dabigatran according to  claim 5 , wherein the lyophilised dabigatran is used as a calibrator agent or a calibrator agent in an anticoagulation assay. 
     
     
         7 - 10 . (canceled) 
     
     
         11 . A kit for the determination of the concentration of dabigatran in a blood sample consisting of an assay for the determination of the concentration of dabigatran in a blood sample together with lyophilised dabigatran according to  claim 5 . 
     
     
         12 . The kit according to  claim 11  wherein the assay for the determination of the concentration of dabigatran in a blood sample comprises a reagent 1 which is human anticoagulated plasma and a reagent 2 which comprises highly purified human thrombin in the a form. 
     
     
         13 . The kit according to  claim 11  wherein reagent 1 and reagent 2 are lyophilised. 
     
     
         14 - 15 . (canceled) 
     
     
         16 . The lyophilized dabigatran according to  claim 5 , wherein the lyophilised dabigatran is used to determine the accuracy of an assay or an anticoagulation assay.

Join the waitlist — get patent alerts

Track US2015240288A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.